Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Status:
Completed
Trial end date:
2016-08-11
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer
receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work
better by making tumor cells more sensitive to the drug